• OPEN AN ACCOUNT
Indian Indices
Nifty
24,426.85 -74.05
(-0.30%)
Sensex
79,809.65 -270.92
( -0.34%)
Bank Nifty
53,655.65 -164.70
( -0.31%)
Nifty IT
35,181.25 -307.50
( -0.87%)
Global Indices
Nasdaq
45,661.67 75.43
(0.17%)
Dow Jones
6,523.31 20.91
(0.32%)
Hang Seng
42,764.54 -64.25
(-0.15%)
Nikkei 225
9,216.82 -38.68
(-0.42%)
Forex
USD-INR
87.60 -0.05
(-0.06%)
EUR-INR
102.16 0.14
(0.13%)
GBP-INR
118.33 0.25
(0.21%)
JPY-INR
0.60 0.00
(0.24%)

EQUITY - MARKET SCREENER

Huhtamaki India Ltd
Industry :  Packaging
BSE Code
ISIN Demat
Book Value()
509820
INE275B01026
162.8195044
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
HUHTAMAKI
21.87
1593.89
EPS(TTM)
Face Value()
Div & Yield %
9.65
2
0.95
 

arrow greentech ltd
Divis Lab slides after Q1 PAT falls 18% QoQ to Rs 545 cr
Aug 06,2025
Revenue from operations also declined 6.79% quarter on quarter (QoQ) to Rs 2,410 crore for the quarter ended 30 June 2025

On a year-on-year (YoY) basis, the company’s net profit rose 26.74%, while revenue increased 13.78%, indicating continued growth over the previous year despite the sequential decline.

Profit before tax for the quarter stood at Rs 733 crore, down 15.16% QoQ but up 21.35% YoY.

The company reported a forex gain of Rs 39 crore during the quarter, compared to a forex loss of Rs 1 crore in the corresponding quarter of the previous financial year.

On a standalone basis, the company’s net profit surged 29.53% to Rs 557 crore on a 14.25% rise in revenue to Rs 2,357 crore in Q1 FY26 over Q1 FY25.

Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.